INNOBLATIVE DESIGNS, Inc

Innoblative Designs, Inc. is a private medical device company founded in 2014 dedicated to developing advanced energy-based surgical solutions that improve care for patients with breast cancer and other soft tissue diseases. The company's flagship product, SIRA (Single-use Intraoperative Radiofrequency Ablation), is an electrosurgical device designed for intraoperative coagulation and ablation of soft tissue during breast-conserving surgery. SIRA has received FDA Breakthrough Device Designation, FDA IDE approval, and CE Mark approval. The company received AMA Category III CPT Code approval for SIRA in March 2026. Innoblative is currently conducting a U.S. feasibility study at the University of Texas Medical Branch (UTMB) enrolling patients in clinical trials.